|View printer-friendly version|
|May 17, 2017 8:00 a.m.|
|Teva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual Meeting|
Data contribute to growing body of evidence supporting the development of deutetrabenazine for the treatment of tardive dyskinesia
“The data accepted for presentation offers additional analyses from two
pivotal Phase III trials, demonstrating the potential of
deutetrabenazine in tardive dyskinesia. This type of research is
representative of Teva’s commitment to improve our understanding of how
to treat this debilitating and undertreated condition,” said
The full set of Teva-sponsored data to be presented includes:
Deutetrabenazine, an investigational treatment for tardive dyskinesia,
is an oral, inhibitor of vesicular monoamine 2 transporter, or VMAT2,
that regulates the levels of neurotransmitters, in the brain.
Deutetrabenazine is approved in
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding deutetrabenazine tablets, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”), including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Pharmaceutical Industries Ltd.